Today’s Landscape

Alzheimer’s disease (AD) is the leading cause of dementia worldwide and is poised to become a major public health crisis. To date, there are few single treatments, pharmaceutical or otherwise, that can help with this degenerative condition.

  Dale Bredesen, MD
The Institute for Functional Medicine, in collaboration with Dale Bredesen, MD, and MPI Cognition, presents a two-day CME program this September, with an exciting new approach to the treatment of early stage AD and mild cognitive impairment (MCI). During this program, attendees will learn a multi-pronged treatment strategy for these patients. Using a systems biology approach, attendees will learn to assess patients for MCI and early AD, stratify them based on the likely causes of their dysfunction, and apply a multimodal protocol to individualize treatments for each patient that address the appropriate underlying causes. In this way, you can arrest cognitive decline and in many cases even reverse it.

IFM’s Reversing Cognitive Decline

Dale Bredesen, MD, describes what clinicians will learn at Reversing Cognitive Decline

Become an expert in not only the latest scientific understanding, but also the tools and interventions that can help these patients. Join IFM and MPI Cognition for the two-day CME program, Reversing Cognitive Decline: Advanced Clinical Training in Alzheimer’s Disease, this September 9-10, 2017, in Dallas, TX.

Clinical Competencies

  • Recognize mild cognitive impairment and early dementia due to Alzheimer's disease and differentiate these from other causes, including non-Alzheimer's dementia.
  • Evaluate the physiological underpinnings of MCI and early AD and the rationale for the systems approach to intervention that utilizes multimodal treatment strategies.
  • Determine which of the six major subtypes of MCI/early AD that a patient has and select appropriate laboratory tests to evaluate the major contributors to each patient’s dysfunction.
  • Explain the critical role of the collaborative care team approach in successfully treating MCI and early AD.
  • Evaluate the importance of technological advances including neuroimaging, cognitive assessments, and therapeutic cognitive training in assessing and treating MCI and early AD.

Disclosure text is not available